MXCT
MXCT
US57777K1060
MaxCyte, Inc.
Loading chart...

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Latest News

Related stocks

CBLL
CBLL • United States
CeriBell, Inc.
23.63 USD
906.87M USD 1Y +89.1%
AHCO
AHCO • United States
AdaptHealth Corp.
6.06 USD
824.49M USD 1Y -32.3%
BBNX
BBNX • United States
Beta Bionics, Inc.
17.63 USD
951.07M USD 1Y -21.2%
LMRI
LMRI • United States
Lumexa Imaging Holdings, Inc.
10.54 USD
1.01B USD
ENOV
ENOV • United States
Enovis Corporation
17.69 USD
1.02B USD 1Y -45.2%
CTKB
CTKB • United States
Cytek Biosciences, Inc.
5.43 USD
705.81M USD 1Y +37.4%
KIDS
KIDS • United States
OrthoPediatrics Corp.
21.65 USD
565.28M USD 1Y +20.2%
AVNS
AVNS • United States
Avanos Medical, Inc.
24.99 USD
1.17B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
68.2% p.a.
Max Drawdown (5Y)
-94.8%
Sharpe Ratio (5Y)
-0.58
Beta Factor
1.49
Size Class
Micro Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (68.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -94.8% in the extended horizon.
ende